⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
GLP-1 Analogues Strategic Business Report 2026: Market to Reach $122.3 Billion by 2030 from $45.3 Billion in 2025 - Strong Pipeline Activity and Strategic Partnerships Fuel Innovations
globenewswire.com
LLY
NVO
COMPUTEX 2026 Brings the Global AI Ecosystem to Taipei
prnewswire.com
MSI
INTC
TXN
NVDA
AMAT
KLAC
LRCX
MU
QCOM
AMD
GOOG
MSFT
AMZN
IBM
DELL
HPQ
VRTX
ADI
NXPI
ON
MCHP
SNPS
CDNS
MRVL
ADSK
CTAS
PAYX
ADP
CRM
NOW
PANW
FTNT
ZBRA
HON
GE
ROK
ETN
GOOGL
META
NFLX
DIS
CMCSA
T
VZ
TMUS
CSCO
ORCL
SAP
ACN
DXC
WDC
SE
SMCI
DDOG
MDB
ZS
CRWD
SNOW
PLTR
UPST
COIN
PYPL
AFRM
SOFI
HOOD
UPWK
FIVN
RBLX
EA
TTWO
U
EXAS
REGN
BIIB
GILD
AMGN
BMY
PFE
MRK
JNJ
ABBV
LLY
NVO
AZN
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
VIPS
EDU
BEKE
TAL
BILI
RLX
XPEV
NIO
LI
CPT
LCID
RIVN
TSLA
GM
F
STLA
VWAGY
HOG
YETI
GOOS
LULU
UA
NKE
ANF
AEO
URBN
PVH
RL
TJX
M
BBY
WMT
COST
TGT
HD
LOW
SPG
PLD
AMT
EQIX
CCI
DLR
SBAC
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
prnewswire.com
LIVN
SNAP
GE
BSX
JNJ
PFE
MRK
BMY
LLY
NVO
PHG
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
CMPX
MRK
PFE
BOLD
REPL
RDHL
RLAY
LLY
INCY
JAZZ
Columbus Rallies to Fund Life-Saving Research and Patient Care Services at Susan G. Komen® 2026 Race for the Cure
businesswire.com
ABT
HMC
NVS
PFE
LLY
BAK
NTRA
Chicago Rallies to Fund Life-Saving Research and Patient Care Services at Susan G. Komen® 2026 Race for the Cure
businesswire.com
NTRA
GH
NVS
LLY
GLP-1 drugs associated with reduced need for emergency care for migraine
prnewswire.com
LLY
NVO
Obesity Care Week 2026 Calls for Action to Improve Access to Obesity Care
prnewswire.com
LLY
GNE
REGN
AMGN
BSX
CURX
NVO
ZETA
Studies explore: GLP-1 receptor agonist use and its impact on long-term musculoskeletal health and orthopaedic surgical outcomes
prnewswire.com
NVO
LLY
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
prnewswire.com
LLY